← brief for 2026-11-03 · Slowing decline

Renal Effects of Dual GLP-1/Glucagon Receptor Agonism: How Should We SYNCHRONIZE With Emerging Evidence in Type 2 Diabetes and Obesity?

Letter No results yet Not peer reviewed

Key takeaways

This is a letter to the editor about a new type of diabetes drug. It discusses how this drug affects the kidneys. It is a short opinion piece, not a full study. There are no new results in this letter.

Who did this work

Patoulias D · Karakasis P · Koufakis T

Source

Letter · PubMed, the drug frontier · 2026 Nov 2
https://pubmed.ncbi.nlm.nih.gov/42972865/